Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30

$161.52+0.73 (+0.45%)

Close on Nov 2, 2026Market cap $308.20BP/E 22.6Yield –

Novartis YoY Growth in the U.S. by Year

Name: Novartis YoY Growth in the U.S. by Year (NVS)
Creator: Novartis

YoY Growth in the U.S. (% USD / cc) (%)

Quarterly Annual

Novartis YoY Growth in the U.S.: 217.0% in FY2025.

Latest, FY2025

217.0%

Period ended Dec 31, 2025

Change on a year earlier

–

History

1 years

Since FY2025

Sources

Novartis Form 6-K (0001114448-26-000007)

Where the FY2025 figure comes from

“|| Fabhalta 4 | Oncology | Paroxysmal Nocturnal Hemoglobinuria (PNH), IgA Nephropathy (IgAN), Adult C3 Glomerulopathy (C3G) | 317 | 217 | 188 | nm | nm | 505 | 291 | 287”

Source: Novartis Form 6-K (0001114448-26-000007) ↗

Reported in Form 6-K & Form 20-F.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Period	Ended	YoY Growth in the U.S. (% USD / cc) (%)	Year on year	Source
FY2025	Dec 31, 2025	217.0%	–	Novartis Form 6-K (0001114448-26-000007) ↗

Cite this data

StockData. (2026). Novartis YoY Growth in the U.S. (%), annual FY2025–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-fabhalta-us-yoy-pct

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.